Q-omics provides the consensus-scored SF3A3 profile across patient tissues and cancer cell-line models. SF3A3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SF3A3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SF3A3 protein abundance shows 31,914 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where SF3A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SF3A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SF3A3 survival associations across molecular data types. SF3A3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SF3A3 RNA expression–survival associations across cancer types. High SF3A3 expression shows unfavorable associations in MESO, ACC, LIHC, KIRP, KICH and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SF3A3 RNA expression.
This table summarizes SF3A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SF3A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SF3A3 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, COAD and STAD. The HNSC box plot shows higher SF3A3 RNA expression in tumor versus normal tissue (log2 FC = +0.611, t-test p < 0.001).
This table shows molecular features associated with SF3A3 in patient tissues and cancer cell lines. In patient samples, SF3A3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SF3A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
